These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21592078)

  • 1. Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar.
    Liu XY; Wang RL; Xu WR; Tang LD; Wang SQ; Chou KC
    Protein Pept Lett; 2011 Oct; 18(10):1021-7. PubMed ID: 21592078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors.
    Miyachi H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.
    Oyama T; Toyota K; Waku T; Hirakawa Y; Nagasawa N; Kasuga JI; Hashimoto Y; Miyachi H; Morikawa K
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):786-95. PubMed ID: 19622862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA; Sylte I
    J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Sep; 44(9):3488-95. PubMed ID: 19268404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome Proliferator-activated Receptors as Potential Targets for Carcinogenic Activity of Polychlorinated Biphenyls: A Computational Perspective.
    Sheikh IA; Khweek AA; Beg MA
    Anticancer Res; 2016 Nov; 36(11):6117-6124. PubMed ID: 27793940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.
    Zoete V; Grosdidier A; Michielin O
    Biochim Biophys Acta; 2007 Aug; 1771(8):915-25. PubMed ID: 17317294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands.
    Laghezza A; Piemontese L; Tortorella P; Loiodice F
    Eur J Med Chem; 2019 Aug; 176():326-342. PubMed ID: 31112893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
    Feldman PL; Lambert MH; Henke BR
    Curr Top Med Chem; 2008; 8(9):728-49. PubMed ID: 18537685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
    Mirza AZ; Althagafi II; Shamshad H
    Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.
    Dixit G; Prabhu A
    Exp Mol Pathol; 2022 Feb; 124():104723. PubMed ID: 34822814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
    Menendez-Gutierrez MP; Roszer T; Ricote M
    Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
    Hong F; Xu P; Zhai Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.
    Laganà AS; Vitale SG; Nigro A; Sofo V; Salmeri FM; Rossetti P; Rapisarda AM; La Vignera S; Condorelli RA; Rizzo G; Buscema M
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
    Pirard B
    J Comput Aided Mol Des; 2003 Nov; 17(11):785-96. PubMed ID: 15072437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
    Cheang WS; Tian XY; Wong WT; Huang Y
    Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.